Form 4: CRISPR Therapeutics COO Julianne Bruno Reports Stock Transactions

Julianne Bruno, COO of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On June 20, 2024, 7,000 restricted stock units (RSUs) vested, each representing one share of CRSP Common Shares.
• Following the vesting, Ms. Bruno sold 3,366 shares on June 21, 2024, at a price of $56.09 per share to cover tax withholding obligations.
• After these transactions, Ms. Bruno directly owns 6,745 Common Shares and indirectly owns 7,088 Common Shares through The Julianne Bruno 2022 GRAT.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's performance and future prospects. The sale of shares to cover tax obligations upon vesting of restricted stock units is a standard practice.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning executive interests with long-term shareholder value.
• Companies like Intellia Therapeutics (NTLA) and Editas Medicine (EDIT), which are also in the gene editing space, have similar executive compensation structures.
• The sale of shares to cover tax obligations upon vesting is a common practice across the industry, ensuring compliance with tax regulations.

Key Dates